CB1 cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men

American Journal of Drug and Alcohol Abuse

Volumn 38, Issue 1, 2012, Pages 114-119

  Goodwin, Robert S ^a   Baumann, Michael H ^b   Gorelick, David A ^a   Schwilke, Eugene ^a   Schwope, David M ^a   Darwin, William D ^a   Kelly, Deanna L ^c   Schroeder, Jennifer R ^a   Ortemann Renon, Catherine ^d   Bonnet, Denis ^d   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d SANOFI   (France)

Author keywords

Antagonist; Cannabis; Cortisol; Rimonabant; Withdrawal

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; DRONABINOL; HYDROCORTISONE; PLACEBO; RIMONABANT;

ARTICLE; CANNABIS ADDICTION; CANNABIS SMOKING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; RANDOMIZED CONTROLLED TRIAL;

DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MARIJUANA ABUSE; PIPERIDINES; PITUITARY-ADRENAL SYSTEM; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL;

EID: 84857602814     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2011.600398     Document Type: Article

References (30)

1. United Nations Office on Drugs and Crime. 2008 World Drug Report. Vienna: United Nations Office on Drugs and Crime, 2008; 310.
2. Hawks RL. The constituents of cannabis and the disposition and metabolism of cannabinoids. In The Analysis of Cannabinoids in Biological Fluids. Research Monograph 42. Hawks R, ed. Rockville: National Institute on Drug Abuse, 1982; 125-137. (Pubitemid 13127565)
3. Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34(5):605-613. (Pubitemid 19007296)
4. Steiner MA, Wotjak CT. Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res 2008; 170:397-432. (Pubitemid 352010245)
5. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 1991; 11(2):563-583.
6. Murphy LL, Munoz RM, Adrian BA, Villanua MA. Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis 1998; 5:432-446. (Pubitemid 29075843)
7. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27(1):73-100. (Pubitemid 43228239)
8. Brown TT, Dobs AS. Endocrine effects of marijuana. J Clin Pharmac 2002; 42:90S-96S. (Pubitemid 35205051)
9. Cone EJ, Johnson RE, Moore JD, Roache JD. Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects. Pharmacol Biochem Behav 1986; 24:1749-1754. (Pubitemid 16066644)
10. Dax EM, Pilotte NS, Adler WH, Nagel JE, Lange WR. The effects of 9-ene-tetrahydrocannabinol on hormone release and immune function. J Steroid Biochem 1989; 34:1-6.
11. Block RI, Farinpour R, Schlechte JA. Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. Drug Alcohol Depend 1991; 28:121-128.
12. D'Souza DC, Ranganathan M, Braley G, Gueorguieva , Zimolo Z, Cooper T, Perry E, Krystal J. Blunted psychotomimetic and amnestic effects of delta-9- tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008; 33(10):2505-2516.
13. Ranganathan M, Braley G, Pittman B, Cooper T, Perry E, Krystal J, D'Souza DC. The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology (Berl) 2009; 203(4):737-744.
14. Pickworth WB, Fant RV. Endocrine effects of nicotine administration, tobacco and other drug withdrawal in humans. Psychoneuroendocrinology 1998; 23(2):131-141. (Pubitemid 28248467)
15. Adinoff B, Iranmanesh A, Veldhuis J, Fisher L. Disturbancesof the stress response: The role of the HPA axis during alcohol withdrawal and abstinence. Alcohol Health Res World 1998; 22(1):67-72.
16. Koob GF. Drug addiction: The yin and yang of hedonic homeostasis. Neuron 1996; 16(5):893-896. (Pubitemid 26171193)
17. Menzaghi F, Rassnick S, Heinrichs S, Baldwin H, Pich EM, Weiss F, Koob GF. The role of corticotropin-releasing factor in the anxiogenic effects of ethanol withdrawal. Ann N Y Acad Sci 1994; 739:176-184.
18. Merlo Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob GF, Weiss F. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 1995; 15(8):5439-5447.
19. de Fonseca FR, Carrera MRA, Navarro M, Koob GF, Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997; 276:2050-2053.
20. Cohen S. The 94-day cannabis study. Ann N Y Acad Sci 1976; 282:211-220.
21. Scheen A, Paquot N. Inhibitors of cannabinoid receptors and glucose metabolism. Curr Opin Clin Nutr Metab Care 2008; 11(4):505-511.
22. Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim E, Walker JM, Nagar S,Ward SJ, Raffa RB. The endocannabinoid system and rimonabant: A new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism-or inverse agonism-as potential obesity treatment and other therapeutic use. J Clin Pharm Therapeut 2007; 32(3):209-231. (Pubitemid 46699514)
23. Tucci SA, Halford JC, Harrold JA, Kirkham TC. Therapeutic potential of targeting the endocannabinoids: Implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr Med Chem 2006; 13(22): 2669-2680. (Pubitemid 44364144)
24. Le Foll B, Gorelick D, Goldberg S. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology 2009; 205(1):171-174.
25. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacology 1999; 141:385-394. (Pubitemid 29190007)
26. Lowe RH, Karschner EL, Schwilke EW, Barnes AJ, Huestis MA. Simultaneous quantification of delta-9- tetrahydrocannabinol (THC), 11-hydroxy-delta-9- tetrahydrocannabinol (11-OH-THC), and 11-nor-delta- 9-tetrahydrocannabinol-9- carboxylic acid (THCCOOH) in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. J Chromatogr A 2007; 1163, 318-327. (Pubitemid 47247721)
27. Levine A, Zagoory-Sharon O, Feldman R, Lewis JG, Weller A. Measuring cortisol in human psychobiological studies. Physiol Behav 2007; 90(1):43-53. (Pubitemid 44918006)
28. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001; 58: 322-330.
29. Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G, Gorelick DA. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) 2007; 194(4):505-515. (Pubitemid 47492992)
30. Fauci AS, et al., eds.. Harrison's Principles of Internal Medicine (17th ed.). New York: McGraw-Hill, Health Professions Division, 2008.